Clinical trial
A Phase I, 2-panel, Open-label, Randomized, Crossover Trial in Healthy Subjects to Investigate the Pharmacokinetic Interaction Between TMC435 and Transporter Substrates, Digoxin and Rosuvastatin
NCT01288742 is registered in ClinicalTrials.gov with Tibotec Pharmaceuticals, Ireland as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I, 2-panel, Open-label, Randomized, Crossover Trial in Healthy Subjects to Investigate the Pharmacokinetic Interaction Between TMC435 and Transporter Substrates, Digoxin and Rosuvastatin
- Lead sponsor
- Tibotec Pharmaceuticals, Ireland
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- January 31, 2011
- Completion date
- May 31, 2011
- Enrollment
- 33 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
hepatitis c virus